Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 17
---
 United Kingdom and the United States. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You should read our Articles of Association, which are filed as an exhibit to the registration statement of which this prospectus forms a part, for the provisions that are important to you.

General

We are a public limited company
organized under the laws of England and Wales under registered number 09216368. Our registered office is 1 Caspian Point, Caspian Way,
Cardiff, CF10 4DQ, United Kingdom. The principal legislation under which we operate and our shares are issued is the Companies Act.

Our issued share capital
as of June 30, 2025 and November 1, 2025 was 61,952,308,922 Ordinary Shares, with each Ordinary Share having a nominal value of £0.000001
per share. Each issued Ordinary Share is fully paid. We currently have 1,000,001 A deferred shares, 4,063,321,418 B deferred shares,
126,547,389,518 C deferred shares, and 2,482,747,137,178 D deferred shares.

There is no limit to
the number of Ordinary Shares that we are authorized to issue, as the concept of authorized capital is no longer applicable under the
provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to any Ordinary
Shares.

We are not permitted
under English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any
of our own Ordinary Shares.

History of Share Capital

Since January 1, 2022,
our issued share capital has changed as provided below.

On March 22, 2022, we issued
one Ordinary Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of
£200 per share.

On May 3, 2022, we issued
1,250 Ordinary Shares to be purchased under our Share Incentive Plan at £0.02 per share to the trust of our Share Incentive Plan.

On August 3, 2022, we issued
warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70 per share.

On September 26, 2022, we
eff